Mark Jerome Pykett is Director at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB). They have made 7 open-market trades across 3 companies since 2004, most recently 2014-06-01.
CIK 0001278271
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $56K since 2004, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NAVB | BUY | 2014-05-09 | 2014-05-13 | $1.34 | $13K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL | 2014-03-10 | 2014-03-11 | $1.96 | $235K | -10.6% | -5.1% | -5.1% |
| NAVB | BUY | 2013-11-08 | 2013-11-08 | $1.35 | $15K | -10.6% | -5.1% | -5.1% |
| NAVB | BUY | 2013-03-15 | 2013-03-18 | $2.70 | $5K | -10.6% | -5.1% | -5.1% |
| NAVB | BUY | 2012-09-11 | 2012-09-14 | $2.64 | $11K | -10.6% | -5.1% | -5.1% |
| NEOP | BUY | 2011-08-22 | 2011-08-23 | $2.60 | $11K | N/A | N/A | N/A |
| ANX | BUY | 2004-05-24 | 2008-04-15 | $2.08 | $1K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.